NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Advances in cancer research have led to an improved understanding of the molecular mechanisms underpinning the development of cancer and how the immune system responds to cancer. This influx of research has led to an increasing number and variety of therapies in the drug development pipeline, including targeted therapies and associated biomarker tests that can select which patients are most likely to respond, and immunotherapies that harness the body's immune system to destroy cancer cells. Compared with standard chemotherapies, these new cancer therapies may demonstrate evidence of benefit and clearer distinctions between efficacy and toxicity at an earlier stage of development. However, there is a concern that the traditional processes for cancer drug development, evaluation, and regulatory approval could impede or delay the use of these promising cancer treatments in clinical practice. This has led to a number of efforts–by patient advocates, the pharmaceutical industry, and the Food and Drug Administration (FDA)–to accelerate the review of promising new cancer therapies, especially for cancers that currently lack effective treatments. However, generating the necessary data to confirm safety and efficacy during expedited drug development programs can present a unique set of challenges and opportunities.
To explore this new landscape in cancer drug development, the National Academies of Sciences, Engineering, and Medicine developed a workshop held in December 2016. This workshop convened cancer researchers, patient advocates, and representatives from industry, academia, and government to discuss challenges with traditional approaches to drug development, opportunities to improve the efficiency of drug development, and strategies to enhance the information available about a cancer therapy throughout its life cycle in order to improve its use in clinical practice. This publication summarizes the presentations and discussions from the workshop.
Contents
Rapporteurs: Sharyl J. Nass, Margie Patlak, Erin Balogh, and Amanda Wagner Gee.
Suggested citation:
National Academies of Sciences, Engineering, and Medicine. 2018. The drug development paradigm in oncology: Proceedings of a workshop. Washington, DC: The National Academies Press. doi: https://doi.org/10.17226/24742.
- NLM CatalogRelated NLM Catalog Entries
- Review Policy Issues in the Clinical Development and Use of Immunotherapy for Cancer Treatment: Proceedings of a Workshop[ 2016]Review Policy Issues in the Clinical Development and Use of Immunotherapy for Cancer Treatment: Proceedings of a WorkshopNational Cancer Policy Forum, Board on Health Care Services, Health and Medicine Division, National Academies of Sciences, Engineering, and Medicine. 2016 Oct 11
- Review Advancing Progress in the Development of Combination Cancer Therapies with Immune Checkpoint Inhibitors: Proceedings of a Workshop[ 2019]Review Advancing Progress in the Development of Combination Cancer Therapies with Immune Checkpoint Inhibitors: Proceedings of a WorkshopNational Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Care Services; National Cancer Policy Forum, Nass SJ, Balogh E. 2019 Jul 12
- Review The FDA Oncology Center of Excellence and precision medicine.[Exp Biol Med (Maywood). 2018]Review The FDA Oncology Center of Excellence and precision medicine.Goldberg KB, Blumenthal GM, McKee AE, Pazdur R. Exp Biol Med (Maywood). 2018 Feb; 243(3):308-312. Epub 2017 Nov 6.
- The project data sphere initiative: accelerating cancer research by sharing data.[Oncologist. 2015]The project data sphere initiative: accelerating cancer research by sharing data.Green AK, Reeder-Hayes KE, Corty RW, Basch E, Milowsky MI, Dusetzina SB, Bennett AV, Wood WA. Oncologist. 2015 May; 20(5):464-e20. Epub 2015 Apr 15.
- Review Expedited Programs for Serious Conditions: An Update on Breakthrough Therapy Designation.[Clin Ther. 2015]Review Expedited Programs for Serious Conditions: An Update on Breakthrough Therapy Designation.Kwok M, Foster T, Steinberg M. Clin Ther. 2015 Sep; 37(9):2104-20. Epub 2015 Aug 18.
- The Drug Development Paradigm in OncologyThe Drug Development Paradigm in Oncology
Your browsing activity is empty.
Activity recording is turned off.
See more...